FINWIRES · TerminalLIVE
FINWIRES

Encounter Resources' Niobium Discovery Further Validates District-Scale Potential of Western Australia Project, Euroz Hartleys Says

By

Encounter Resources' (ASX:ENR) new high-grade niobium discovery at the Joyce prospect further validates the district-scale potential of its Aileron project in Western Australia, Euroz Hartleys said in a Monday note.

The company's air-core drilling returned four meters at 2.4% niobium pentoxide from 40 meters to the end of the hole, and six meters at 1.3% niobium pentoxide from 88 meters to the end of the hole.

"The latest results highlight significant regional upside and the potential to add additional shallow, high-grade niobium resources beyond the main Green resource zone," the equity research firm said.

It added that planned follow-up drilling along strike and at depth is expected to better define the scale of the Joyce discovery, with mineralization remaining open both laterally and at depth. Three rigs remain active, with further Joyce results expected in October.

Euroz Hartleys maintained a speculative buy rating on Encounter Resources, saying that the investment case continues to strengthen as Aileron advances on multiple fronts, with an unchanged target price of AU$0.85 per share.

Encounter Resources shares fell 6% in recent Monday trade.

What else is happening in Asia?

Asia

Orora Chief Safety, Sustainability, Governance Officer to Step Down at End of Year

Orora (ASX:ORA) said Ann Stubbings plans to step down as chief safety, sustainability, and governance officer, effective Dec. 31, after more than 13 years with the packaging products firm, according to a Monday filing with the Australian bourse.In addition, Susannah Jobling Hodgens will be appointed as chief legal officer, the company said. Hodgens has worked with Orora for 13 years in senior legal and governance roles, most recently as general counsel and alternate company secretary.Orora shares gained nearly 1% in recent Monday trade.

ASX:ORA
Asia

Biokin Pharma Enrolls First Patient in Phase Three Trial for Breast Cancer Drug; Shares Up 4%

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the third-phase clinical trial of biologic drug T-Bren for injection, according to a weekend filing with the Shanghai bourse.The trial evaluates T-Bren combined with pertuzumab versus standard chemotherapy in neoadjuvant treatment of HER2-positive breast cancer, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 4% in recent trade.

SHA:688506
Asia

Market Chatter: Korea Exchange to Extend Trading Hours till 8PM

South Korea's main stock market, the Korea Exchange, will enable trading till 8 pm following the regular close at 3:30 pm from Monday, in its move toward 24-hour trading, Bloomberg News reported Sunday.This decision opens 2,400 Korea Composite Stock Price Index, or Kospi, and Kosdaq stocks for evening trades, which include short-selling. The move excludes exchange-traded funds, the report said.The Korea Exchange plans to introduce pre-market trading by the end of next year, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

^KOSDAQKOSPI